Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) — Helus
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
Dr. Kramer’s 25 years’ of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) — Helus Pharma TM (Nasdaq: HELP) (Cboe CA: HELP), a clinical
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industry Appointment supports Helus Pharma’s continued maturation as the company advances its novel clinical pipeline NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) —
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
Statistically significant (p
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35) versus placebo at two weeks Antidepressant treatment effects observed within one week and
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
– Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events – – Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder (“GAD”) expected in Q1 2026 – This news release constitutes a “designated news release” for the
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLC Proven leader in late-stage clinical development,
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq
Helus Pharma builds on the strong foundation originally created as Cybin Inc. , reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
TORONTO –(BUSINESS WIRE)–Dec. 30, 2025– Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today